Ilona Bebenek

An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

Amy M. Avila, Ilona Bebenek, Jessica A. Bonzo et al. · Regulatory Toxicology and Pharmacology · 2020 · 176 citations

Fda/cder Perspective, Preclinical Drug Evaluation, Pharmacology +8

Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies

Amy M. Avila, Ilona Bebenek, Donna L. Mendrick et al. · Regulatory Toxicology and Pharmacology · 2023 · 41 citations

Fda/cder Perspective, Preclinical Drug Evaluation, Health Policy +9

Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies

Vijay P. Kale, Ilona Bebenek, Hanan Ghantous et al. · International Journal of Toxicology · 2022 · 15 citations

COVID-19 Therapeutics and Vaccines: A Race to Save Lives

Ilona Bebenek, Roy Bannister, John Dubinion et al. · Toxicological Sciences · 2021 · 13 citations · Full text

Immunology, Immunotherapeutics, Antiviral Drug +19

Drug Development 101: A Primer

Lorrene A. Buckley, Ilona Bebenek, Paul D. Cornwell et al. · International Journal of Toxicology · 2020 · 10 citations · Full text